Korean J Perinatol.
2011 Mar;22(1):57-63.
The Therapeutic Effect of Inhaled Iloprost in Newborn Infants with Severe Persistent Pulmonary Hypertension Refractory to Inhaled Nitric Oxide
- Affiliations
-
- 1Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea. ranng@yuhs.ac
Abstract
- Inhaled iloprost, a stable carbacyline derivative of prostacyclin, has been used recently for the treatment of adults with pulmonary hypertension but only few reports are available about its use in neonatal critical care. We report therapeutic trial of inhaled iloprost in newborn infants with persistent pulmonary hypertension of the newborn (PPHN) who did not respond to inhaled nitric oxide (iNO). Inhaled iloprost (Ventavis(R), Bayer Shering Pharma, Germany) was effective in neonates with severe PPHN who showed inadequate response to iNO. We suggest that inhaled iloprost could be considered as an additional therapeutic option in PPHN refractory to iNO.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A case of persistent pulmonary hypertension of the newborn: Treatment with inhaled iloprost
- Inhaled Iloprost as a First-Line Therapy for Persistent Pulmonary Hypertension of the Newborn
- Use of Inhaled Iloprost in an Infant With Bronchopulmonary Dysplasia and Pulmonary Artery Hypertension
- Prognosis and Side Effects of Inhaled Nitric Oxide Treatment in Persistent Pulmonary Hypertension of the Newborn
- Inhaled Nitric Oxide as a Therapy for Pulmonary Hypertension after Operations for Congenital Heart Diseases
